Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer

Endocrine-Related Cancer

Volumn 19, Issue 5, 2012, Pages 725-730

  Sasaki, Takeshi ^a   Onishi, Takehisa ^a   Hoshina, Akira ^a  

^a ISE RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICARTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DISEASE COURSE; HUMAN; KAPLAN MEIER METHOD; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; REFERENCE VALUE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867414249     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-12-0133     Document Type: Article

References (20)

1. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ et al. 2010 Effect of dutasteride on the risk of prostate cancer. New England Journal of Medicine 362 1192-1202. (doi:10.1056/NEJMoa0908127)
2. Arai Y, Yoshiki T & Yoshida O 1990 Prognostic significance of prostate specific antigen in endocrine treatment for prostatic cancer. Journal of Urology 144 1415-1419.
3. Calais da Silva FE, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, Kirkali Z, Calais da Silva FM & Robertson C 2009 Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. European Urology 55 1269-1277. (doi:10.1016/j.eururo.2009.02.016)
4. Choueiri TK, Xie W, D'Amico AV, Ross RW, Hu JC, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O et al. 2009 Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115 981-987. (doi:10.1002/cncr.24064)
5. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR & Akaza H 2009 Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. Journal of Clinical Oncology 27 4306-43136. (doi:10.1200/JCO.2008.21.5228)
6. De Voogt HJ, Suciu S, Sylvester R, Pavone-Macaluso M, Smith PH & de Pauw M 1989 Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on Treatment of Cancer trials. Journal of Urology 141 883.
7. Eisenberger MA & Carducci M 2007 Treatment of hormone-refractory prostate cancer. In Cambell-Walsh Urology, vol 3, 9th edn, pp 3101-3117. Eds AJ Wein, LR Kavoussi, AC Novick, AW Partin & CA Peters. Philadelphia, PA, USA: Sounders.
8. Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN & Gnanapragasam VJ 2011 Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in menwith bone scan negative prostate cancer. Journal of Cancer Research and Clinical Oncology 137 235-241. (doi:10.1007/s00432-010-0877-9)
9. Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Huang CY, Pu YS, Yu CC & Huang CH 2011a Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate 71 1189-1197. (doi:10.1002/pros.21334)
10. Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Liu CC, Huang CY, Pu YS, Yu CC, Wu TT et al. 2011b Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy. Aging Male 15 34-41. (doi:10.3109/13685538.2011.580398)
11. Ishikawa S, Soloway MS, Van der Zwaag R & Todd B 1989 Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. Journal of Urology 141 1139-1142.
12. Japanese Urological Association 2001 In General rule for clinical and pathological studies on prostate cancer. 3rd edn, pp 84-87. Tokyo, Japan: Kanehara Syuppan.
13. Knudsen KE, Arden KC & Cavenee WK 1998 Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells. Journal of Biological Chemistry 273 20213-20222. (doi:10.1074/jbc.273.32. 20213)
14. Kwak C, Jeong SJ, Park MS, Lee E & Lee SE 2002 Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. Journal of Urology 168 995-1000. (doi:10.1016/S0022- 5347(05)64559-4)
15. Matzkin H, Eber P, Todd B, van der Zwaag R & Soloway MS 1992 Prognostic significance of changes in protate-specific markes after endocrine treatment of stage D2 prostate cancer. Cancer 70 2302-2309. (doi:10.1002/1097- 0142(19921101)70:9〈2302::AID-CNCR2820700915〉3.0.CO;2-2)
16. Morote J, Trilla E, Esquena S, Abascal JM & Reventos J 2004 Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. International Journal of Cancer 108 877-881. (doi:10.1002/ijc.11639)
17. Onishi T, Yamakawa K, Franco OE, Kawamura J, Watanabe M, Shiraishi T & Kitazawa S 2001 Mitogen-activated protein kinase pathway is involved in a6 integrin gene expression in androgen-independent prostate cancer cells: role of proximal Sp1 consensus sequence. Biochimica et Biophysica Acta 1538 218-227. (doi:10.1016/S0167-4889(01)00068-4)
18. Sasaki T, Onishi T & Hoshina A 2011 Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis. Prostate Cancer and Prostatic Diseases 14 248-252. (doi:10.1038/pcan.2011.14)
19. Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S & Moinuddin M 1988 Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 61 195-202. (doi:10.1002/1097-0142(19880101)61:1〈195::AID-CNCR2820610133〉3.0. CO;2-Y)
20. Yeung F, Li X, Ellett J, Trapman J, Kao C & Chung LW 2000 Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. Journal of Biological Chemistry 275 40846-40855. (doi:10.1074/jbc.M002755200)